HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin

Digestive Diseases and Sciences

Volumn 45, Issue 6, 2000, Pages 1103-1108

  Kurosaki, Mariko ^a   Takagi, Hitoshi ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Cholestasis; Drug; Jaundice; Major histocompatibility antigen; Mercaptopropionyl glycine

Indexed keywords

TIOPRONIN;

ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; DISEASE PREDISPOSITION; FEMALE; HLA SYSTEM; HUMAN; IMMUNOGENETICS; JAUNDICE; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER INJURY; LYMPHOCYTE TRANSFORMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL;

ADULT; AGED; CHOLESTASIS, INTRAHEPATIC; FEMALE; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR6 ANTIGEN; HUMANS; MALE; MIDDLE AGED; THIOPRONINE;

EID: 0034088284     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005585515826     Document Type: Article

References (36)

1. 1. Pessayer D, Larrey D: Drug-induced liver injury. In Oxford Textbook of Clinical Hepatology, Vol 2. N McIntyre, JP Benhamou, J Bircher, M Rizzetto, J Rodes (eds). Oxford, Oxford University Press, 1991, pp 875-902
2. 2. Kaplowitz N, Aw TY, Simon FR, Stolz-A: Drug-induced hepatotoxicity. Ann Intern Med 104:826-836, 1986
3. 3. Zimmerman HJ: Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. New York, Appleton Century Crofts, pp 110-114, 1978
4. 4. Stricker BH, Spoelstra P: Drug-Induced Hepatic Injury. A Comprehensive Survey of the Literature on Adverse Drug Reactions Up to January. Amsterdam, Elsevier, 1985, pp 98-120
5. 5. Mita I: Chemistry, pharmacology and current clinical applications of tiopronin. In Recent Advances in 2-MPG Treatment of Liver Disease. R Williams, G Gasbarrini, M Davis (eds). Osaka, Santen Pharmaceutical Co, 1981, pp 1-10
6. 6. Sany J, Combe B, Verdie-Petibon D, Tagemouati A, Daures JP: Long-term tolerability of tiopronin (Acadione) in the treatment of rheumatoid arthritis. Apropos of 140 personal cases. Rev Rum Mal Osteoartic. 57:105-111, 1990
7. 7. Ichikawa S, Kitami N: A study of clinical features in patients with drug induced allergic hepatic injury. Acta Hepatol Jpn 30:553-558, 1989 (in Japanese, abstract in English)
8. 8. Tsude K, Morioka Y, Murata H, Morishita A, Yishida K, Hujiyama S, Satou T: Two cases of tiopronin induced liver injury. Gendaiiryo 21:1266-1267, 1989 (in Japanese)
9. 9. Maeyama S, Murakami T, Satoh H: Tiopronin induced liver injury - Clinical investigation. St. Marianna Med J 14:571-582, 1986 (in Japanese)
10. 10. Tsutsui H, Terano Y, Sakagami C, Hasegawa I, Mizoguchi Y, Morisawa S: Drug-specific T cells derived from patients with drug-induced allergic hepatitis. J Immunol 149:706-716, 1992
11. 11. Sherlock S: The syndrome of disappearing intrahepatic bile ducts. Lancet 2:493-496, 1987
12. 12. Berson A, Freneaux E, Larrey D, et al: Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyneratic hepatitis. J Hepatol 20:336-342, 1994
13. 13. Ju LY, Paolozzi L, Delecoeuillerie G, et al: A possible linkage of HLA-DRB haplotype with tiopronin intolerance in rheumatoid arthritis. Clin Exp Rheumatol. 12:249-254, 1994
14. 14. Bardin T, Dryll A, Debeyre N, Ryckewaert A, Legrand L, Marcellia A, Dausset J: HLA system and side effects of gold salts and D-penicillamine treatment of rheumatoid arthritis. Ann Rheumtol Dis 41:599-601, 1982
15. 15. Dequecker J, Van Wanghe P, Verdickt W: A systematic survey of HLA-A, B, C, and D antigens and drug toxicity in rheumatoid arthritis. J Rheumatol 11:282-286, 1981
16. 16. Wooly PH, Griffin J, Panayi GS, Batchelor JR, Weilis KI, Gibson TJ: HLA-DR antigens and toxic reactions to sodium autothiomalate and D-penicillamine in patients with rheumatoid arthiris. N Engl J Med 303:300-302, 1980
17. 17. The Group of Drugs and the Liver. Criteria of drug-induced liver injury. Proceedings of drugs and the liver, 1978, 3rd meeting. Toryou Print, Tokyo, p 96
18. 18. Brenichou C, Council for International Organization of Medical Sciences (CIOMS): Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11:272-276, 1990
19. 19. Yoshimasu H: Clinical study of drug induced liver injury. Acta Hepatol Jpn 26:189-200, 1985 (in Japanese, abstract in English)
20. 20. Terasaki PI, McClelland JD: Microdroplet assay of human serum cytotoxins. Nature 204:998-1000, 1964
21. 21. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y: Microdroplet testing for HLA-A, B, C, and D antigens. Am J Clin Pathol 69:103-120, 1978
22. 22. Aizawa M: Antigen and gene frequencies of ethnic groups. In HLA Asia-Oceania. Hokkaido University Press, Sapporo, 1986, pp 1080-1103
23. 23. Stricker BHCh, Block R, Class FHJ, Parys GEV, Desmet VJ: Hepatic injury associated with the use of nitrofurans: A clinicopathological study of 52 reported cases. Hepatology 8:599-606, 1988
24. 24. Pariente A, Hamoud A, Goldfain D, et al: Hépatities a la clometacine (Duperan). Etude rétrospective de 30 cas. Un modèle d’hépatite immunoallérgique. Gastroenterol Clin Biol 13:769-774, 1989
25. 25. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T: Estimation of allele and haplotype frequencies for HLA and complement locus HLA. 1991, Vol 1. Tsuji K et al. (eds). Oxford, Oxford University Press, 1992, pp 76-79
26. 26. Charron D: Appendix B. HLA allele and haplotype frequencies by DNA typing: Local assignment. In Genetic Diversity of HLA. Functional and Medical Implications. D Charron (ed). 1997, pp 712-725
27. 27. Ferraccioli GF, Cavalier F, Mercadante M, Salaffi F, Ambanelli U, Save M: Association between DR3 and thrombocytopenia due to gold or tiopronin. Clin Exp Rheumatol 3:341-343, 1985
28. 28. Ferraccioli GF, Peri F, Nervetti A, Amanelli U, Save M: Toxicity due to remission including drugs in rheumatoid arthritis. Association with HLA-B35 and Cw antigens. J Rheumatol 13:65-68, 1986
29. 29. Matsushita S, Takahashi K, Motoki M, Komoriya K, Ikagwa S, Nishimura Y: Allele specificity of structural requirement for peptides bond to HLA-DRB1*0405 and DRB1*0405 complexes: Implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J Exp Med 180:873-883, 1994
30. 30. Kenna JG, Satoh H, Christ DD, Pohl LR: Metabolic basis for a drug hypersensitivity: Antibodies in sera from patients with trifluoroacctyl group derived from halothane. J Pharmacol Exp Ther 25:11103-11109, 1988
31. 31. Beaune P, Daunsette PM, Mansuy D, et al: Human antimicrosome antibodies appearing in a drug-induced hepatitis are directed against cytovhrome P-450 hydroxylating the drug. Proc Natl Acad Sci USA 84:551-555, 1987
32. 32. Bourdi M, Larrey D, Nataf J, et al: Anti-liver endoplasmic reticulum autoantibodies are directed against cytochrome P-450-1A2. A specific marker of dihydralazine hepatitis. J Clin Invest 85:1967-1973, 1990
33. 33. Maria VAJ, Victorino RMM: Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 41:534-540, 1997
34. 34. Kitashiro M, Hirohata M, Suwaki K: Tiopronin induced intrahepatic cholestasis - the treatment of hyperbilirubinemia with plasma absorption. J Sanpou Sougou Hosp 9:125-130, 1988 (in Japanese)
35. 35. Ayres RC, Neuberger JM, Shaw J, Joplin R, Adams DH: Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells; Effects of pro-inflammatory cytokines. Gut 34:1245-1259, 1993
36. 36. Banner BF, Allan C, Smith L, Savas L, Bonkovsky HL: Effect of interferon therapy on bile duct inflammation in hepatitis C. Virchows Arch 428:253-259, 1996